Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy of WBC100 Capsules in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT07014449 is registered in ClinicalTrials.gov with Hangzhou Weben Pharma Co., Ltd as lead sponsor.

NCT NCT07014449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07014449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy of WBC100 Capsules in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Lead sponsor
Hangzhou Weben Pharma Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
November 3, 2024
Completion date
June 30, 2026
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult acute myeloid leukemia, aml (acute myelogenous leukemia, c-myc, hematologic malignancy, refractory acute myeloid leukemia, relapsed acute myelogenous leukemia